Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Flu jab – convenient, safe and long-term

09.12.2005


Strictly speaking, the ‘choked’, i.e., inactivated three viruses (A1, A2, B) in the new vaccine will be the same as before. They are included in the vaccine composition on the recommendation of the World Health Organisation. But the additional substances, however, proposed by the researchers, are what make it possible to make this vaccine in tablet form. What is more, believe the authors, this vaccine will be more efficient than all known equivalents. Not because an injection is replaced with a tablet, but because the authors propose to include a so-called adjuvant into the vaccine composition; put simply – an enhancer for the effect of the vaccine. The scientists are already confident of its effectiveness: A similar, intranasal vaccine which they developed previously (what specialists call nasal drops) with the same adjuvant is already at clinical trial stage. The first volunteers will be testing it in the first clinical trials this autumn.



So, the most important component of this vaccine is Korauban, an original immunostimulant, or a substance that intensifies immunity. Its correct name is a stimulant of immunogenesis, a gamma-interferon inductor. This is a close relative of regular cellulose; the same polysaccharide, only of a slightly different structure. It is produced by ‘specially trained’ microorganisms and it serves to enhance the action of the vaccine.

Korauban, if we are to greatly simplify the matter, calls special cells, which are to eliminate alien elements, to where the decontaminated virus has struck, and it presents the enemy to them. As a result the organism strenuously produces protection – special proteins (antibodies) and cells, both directed to the form of the enemy. What is of especial importance is that, as a result, humans produce so-called local cell immunity, of a long-term and wide-ranging action; not only against the used vaccine and existing epidemic viruses, but also against the pathogens of future epidemics. And in the region of the nose and throat. It is with damage to the latter, incidentally, that the illness begins. In the first days flu usually passes without a cold.


‘The combination of Korauban and vaccine viruses in one preparation leads to a synergy of their action,’ states Project manager Oleg Kuznetsov. ‘This is displayed in an increase in early synthesis of common interferon, a factor of the synthesis of intensified non-specific resistance of the organism to bacterial and viral infections. Obviously the preparation could be applied for emergency protection not only from flu but also from other acute respiratory viral infections. Such a protection would suffice for a week; further, a specific protection against flu will begin to act’.

Finally, there is another substance in the composition of the tablet, which ensures the tablet-vaccine remains stable for a 12-month period. The scientists will obtain the first clinical test results no earlier than next Spring. For now it will be in the form of drops in aerosol form and not tablets. However, the authors are confident of its success. The vaccine demonstrated high efficiency on laboratory animals and proved to be completely non-toxic. The researchers believe that this ‘jab’ will need to be taken once every few years. The sooner the better.

Andrew Vakhliaev | alfa
Further information:
http://tech-db.istc.ru/istc/sc.nsf/html/hi-tech.htm

More articles from Life Sciences:

nachricht Multi-institutional collaboration uncovers how molecular machines assemble
02.12.2016 | Salk Institute

nachricht Fertilized egg cells trigger and monitor loss of sperm’s epigenetic memory
02.12.2016 | IMBA - Institut für Molekulare Biotechnologie der Österreichischen Akademie der Wissenschaften GmbH

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>